Medical Students Know the Genetics of Personalized Diabetes Care but Feel Unready to Use It

Imagine a future where a simple genetic test tells your doctor exactly which diabetes drug will work best for you, at what dose, and with the lowest risk of side effects. That future is the promise of pharmacogenomics, the branch of precision medicine that studies how genetic variation shapes individual responses to medications. But a new study from Palestine suggests that even the most motivated future doctors may not be prepared to deliver on that promise. The research, published in BMC Medical Education, surveyed hundreds of undergraduate medical students and uncovered a striking paradox: most students understood the core concepts of pharmacogenomics, yet very few felt ready to apply them at the bedside.

The study, led by researchers at Al-Quds University in Jerusalem, set out to measure knowledge, attitudes, readiness, and ethical concerns about precision medicine and pharmacogenomics in diabetes care among medical students across Palestinian universities. Diabetes was chosen as the clinical focus for good reason. Patients with type 2 diabetes can respond very differently to commonly prescribed antidiabetic medications, and genetic differences are increasingly recognized as one driver of that variability. As genomic testing becomes cheaper and more widely available, the question of whether newly trained physicians can actually use this information is becoming urgent in health systems everywhere, not only in the Middle East.

Between June and August 2026, the team conducted a multicenter cross-sectional study using a self-administered online questionnaire. The instrument covered sociodemographic characteristics, educational background, and several carefully structured assessment domains. Knowledge was tested with eighteen true-or-false questions probing the scientific foundations of pharmacogenomics and its application to diabetes treatment. Attitudes, readiness, and ethical concerns were measured with five-point Likert-scale items, a standard survey technique that asks respondents to rate their agreement with statements on a scale ranging from strong disagreement to strong agreement. The researchers then analyzed the responses using descriptive statistics, chi-square tests, Kruskal-Wallis tests, and multivariable logistic regression, a modeling approach that allows investigators to determine which factors independently predict an outcome while controlling for the influence of other variables.

The headline numbers tell a nuanced story. Among the 352 students who participated, 62.2 percent, or 219 individuals, demonstrated adequate knowledge of precision medicine and pharmacogenomics. That is a respectable figure, suggesting that the conceptual building blocks of genomic medicine are reaching students through lectures, textbooks, and self-directed learning. Yet when the researchers turned to attitudes, only 29.3 percent, or 103 students, expressed favorable attitudes toward these technologies. And readiness, the measure of whether students felt prepared to actually use pharmacogenomic information in clinical decision-making, was even lower: just 18.8 percent, or 66 students, met the criterion for readiness. In other words, knowing the science is not the same as being able to practice it.

What separated the well-prepared students from the rest? The regression analysis identified several independent predictors. Greater experience with diabetes pathogenesis and treatment was associated with both adequate knowledge, with an odds ratio of 1.78 and a 95 percent confidence interval of 1.36 to 2.34, and favorable attitudes, with an odds ratio of 1.32 and a confidence interval of 1.06 to 1.65. An odds ratio above 1 means the factor increases the likelihood of the outcome, and because these confidence intervals do not cross 1, the associations are statistically meaningful. Students who had dug deeper into how diabetes develops and how it is treated simply knew more and felt more positive about genomic approaches to care.

Readiness followed a different logic. It was independently associated with greater experience in biostatistics, with an odds ratio of 1.55 and a confidence interval of 1.17 to 2.06, and with previous formal study of genetics, with an odds ratio of 5.17 and a confidence interval of 1.21 to 22.15. That last figure is remarkable: students who had previously studied genetics were more than five times as likely to feel ready to apply pharmacogenomics in practice. The finding makes intuitive sense. Applying genomic medicine requires the confidence to interpret genetic data, weigh probabilities, and translate laboratory results into treatment decisions, and that confidence appears to be built through direct exposure to genetics coursework and quantitative training rather than through general clinical knowledge alone.

The relationships among the three main outcomes were also revealing. Knowledge was significantly associated with both attitudes and readiness, but the strongest link appeared between attitudes and readiness, measured with a Cramér’s V statistic of 0.39 and a p-value below 0.001. Cramér’s V is a measure of association that ranges from 0 to 1, where higher values indicate stronger relationships between categorical variables. A value of 0.39 suggests a moderate-to-strong connection, meaning that students who viewed pharmacogenomics favorably were much more likely to feel ready to use it. This pattern hints at a psychological pathway: positive attitudes may be a necessary bridge between theoretical knowledge and genuine clinical preparedness, which has direct implications for how educators should design curricula.

Perhaps the most consequential findings concern the curriculum itself. Only 23 percent of the surveyed students believed that pharmacogenomics was adequately covered in their medical education. Yet demand for the subject was overwhelming: 89.2 percent of students supported its inclusion in the curriculum, and 90.9 percent wanted additional training. That gap between what is taught and what students want to learn represents both a problem and an opportunity. The problem is a generation of future physicians entering practice without the tools to interpret an expanding stream of genomic information. The opportunity is an unusually receptive audience; few areas of medical education enjoy near-unanimous student demand, and the authors argue that their findings support integrating structured, clinically oriented, and experiential pharmacogenomics education into medical curricula in Palestine.

Ethical concerns, often cited as a barrier to genomic medicine, formed another dimension of the survey. While the study found that students held measurable concerns about issues such as privacy and the implications of genetic testing, the dominant pattern in the data was enthusiasm constrained by lack of preparation. This matters because the successful deployment of pharmacogenomics depends not only on laboratory technology but on clinicians who can explain genetic results to patients, obtain meaningful informed consent, and navigate questions about data security and equitable access. Education that ignores the ethical dimension risks producing physicians who are technically capable but unprepared for the conversations that genomic medicine inevitably triggers in the clinic.

The broader lesson extends well beyond Palestine. Health systems worldwide are grappling with how to move pharmacogenomics from research papers into routine prescribing, and workforce readiness has emerged as a universal bottleneck. This study offers a template for measuring that readiness and a clear diagnosis of where the pipeline breaks: conceptual knowledge is being transmitted, but the applied, statistical, and ethical competencies that turn knowledge into practice are not. The authors received ethical approval from the Al-Quds University Research Ethics Committee, conducted the work without external funding, and published their findings open access so that educators elsewhere can build on them. If the next generation of doctors is to prescribe drugs matched to a patient’s DNA rather than to a population average, medical schools will need to close the gap this study has so precisely measured, and they will need to do it before their students graduate into clinics where genomic data is already waiting in the chart.

Subject of Research: Medical students' knowledge and readiness for pharmacogenomics in diabetes care

Article Title: Knowledge and readiness toward precision medicine and pharmacogenomics in diabetes care among medical students: a cross-sectional study

Article References: Faroun, J., Ayasa, Y., Madaka, S., Alayasa, S., Bael, P., & Ereqat, S. (2026). Knowledge and readiness toward precision medicine and pharmacogenomics in diabetes care among medical students: a cross-sectional study. BMC Medical Education. https://doi.org/10.1186/s12909-026-10548-5

Image Credits: AI Generated

DOI: 10.1186/s12909-026-10548-5

Keywords: pharmacogenomics, precision medicine, diabetes, medical education, medical students, genetics, curriculum, cross-sectional study, clinical readiness, Palestine, biostatistics, personalized medicine